NCT06082557View on ClinicalTrials.gov

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Malignant Solid Tumors
Interventions
DRUG

T60c injection

"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06082557 - A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | Biotech Hunter | Biotech Hunter